全球僵直性脊椎炎市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計僵直性脊椎炎市場將從 2025 年的 71.1 億美元成長到 2034 年的 127.1 億美元，2026 年至 2034 年的複合年成長率為 6.66%。

僵直性脊椎炎)的全球市場持續穩定成長，這主要得益於診斷率的提高和人們對發炎性自體免疫疾病認知的增強。影像技術的進步和早期篩檢通訊協定的建立使得僵直性脊椎炎的早期發現成為可能，尤其是在年輕患者群體中。慢性腰痛盛行率的不斷上升，以及遺傳易感性的存在，進一步推動了已開發市場和新興市場對生物目標製劑和先進治療方法的需求。

成長要素包括TNF抑制劑和IL-17抑制劑等生物製藥療法的廣泛應用，以及已開發國家醫保覆蓋範圍的擴大。製藥公司正大力投資研發，以推出療效和安全性更高的新一代生物製藥。此外，患者支持活動和宣傳宣傳活動提高了公眾對疾病的認知，加快了治療啟動速度，並擴大了目標患者群體。

展望未來，生物相似藥的上市、精準醫療方法的應用以及免疫學研究的進展預計將推動市場強勁成長。新興市場有望受益於醫療基礎設施的改善和醫療費用支出的增加而顯著成長。與數位醫療的融合，實現遠端監測和用藥依從性追蹤，將進一步改善患者療效，並推動僵直性脊椎炎市場實現持續的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球僵直性脊椎炎市場：依藥物類別分類

• 市場分析、洞察與預測
• 非類固醇消炎劑（NSAIDs）
• TNF抑制劑
• 其他藥物類別

第5章 全球僵直性脊椎炎市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 其他

第6章 全球僵直性脊椎炎市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • Amgen Inc
  • Pfizer Inc
  • UCB Inc
  • Novartis AG
  • Eli Lilly And Company
  • Johnson And Johnson Services Inc
  • Merck And Co. Inc
  • Izana Biosciences
  • Zydus Lifescience Ltd

The Ankylosing Spondylitis Market size is expected to reach USD 12.71 Billion in 2034 from USD 7.11 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The Global Ankylosing Spondylitis Market is experiencing steady expansion driven by rising diagnosis rates and increasing awareness of inflammatory autoimmune disorders. Improved imaging technologies and earlier screening protocols are enabling timely identification of ankylosing spondylitis, particularly among younger populations. The growing burden of chronic back pain and genetic predisposition factors are further contributing to demand for targeted biologics and advanced therapeutic interventions across developed and emerging healthcare systems.

Key growth drivers include the strong adoption of biologic therapies such as TNF inhibitors and IL-17 inhibitors, alongside expanding reimbursement coverage in developed economies. Pharmaceutical companies are investing heavily in research and development to introduce next-generation biologics with improved efficacy and safety profiles. Additionally, patient advocacy initiatives and educational campaigns are improving disease awareness, thereby accelerating treatment uptake and expanding the addressable patient pool.

Looking ahead, the market is poised for robust growth fueled by biosimilar launches, precision medicine approaches, and advancements in immunology research. Emerging markets are expected to contribute significantly due to improving healthcare infrastructure and rising healthcare expenditure. Digital health integration for remote monitoring and adherence tracking will further enhance patient outcomes, positioning the ankylosing spondylitis market for sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Non-Steroidal Anti-Inflammatory Drug (NSAID)
• TNF Inhibitors
• Other Drug Classes

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

COMPANIES PROFILED

• AbbVie Inc, Amgen Inc, Pfizer Inc, UCB Inc, Novartis AG, Eli Lilly and Company, Johnson and Johnson Services Inc, Merck and Co Inc, Izana Biosciences, Zydus Lifescience Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Non-Steroidal Anti-Inflammatory Drug (NSAID) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. TNF Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Class
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Class
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Class
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Class
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Class
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ANKYLOSING SPONDYLITIS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AbbVie Inc
  • 8.2.2 Amgen Inc
  • 8.2.3 Pfizer Inc
  • 8.2.4 UCB Inc
  • 8.2.5 Novartis AG
  • 8.2.6 Eli Lilly And Company
  • 8.2.7 Johnson And Johnson Services Inc
  • 8.2.8 Merck And Co. Inc
  • 8.2.9 Izana Biosciences
  • 8.2.10 Zydus Lifescience Ltd